Company · Toronto, Ontario, Canada
Teva Canada Limited
Everything this company holds in Health Canada’s product databases, as the company’s name is spelled there.
- Drug products (DIN)
- 1,484
- 708 authorized now
- Natural health products
- 99
- 85 active licences
- Medical device licences
- 6
- 0 active
- Notices of Compliance
- 1,441
Drug products
Authorized products first.
Showing 300 of 1,484 drug products. For the rest, search Health Canada’s database.
Natural health products
Active licences first, newest first.
Medical device licences
Active licences first, newest first.
| Name | Licence | Status | First licensed |
|---|---|---|---|
| NOVO-GLUCOSE STRIPS | 11500 | Discontinued at renewal · Class 3 | |
| KNOW NOW MENOPAUSE TEST | 13301 | Discontinued at renewal · Class 2 | |
| KNOW-NOW CHOLESTEROL TEST | 5085 | Discontinued at renewal · Class 2 | |
| KNOW-NOW OVULATION TEST | 5089 | Discontinued at renewal · Class 2 | |
| KNOW-NOW PREGNANCY TEST | 5096 | Discontinued at renewal · Class 2 | |
| KNOW-NOW BLOOD PRESSURE METER | 3069 | Discontinued at renewal · Class 2 |
Notices of Compliance
Newest first.
- LEUCOVORIN CALCIUM INJECTIONOctober 9, 2026 · NOC 38443 · Supplement to a New Drug Submission (SNDS)
- TEVA-SALBUTAMOL HFAOctober 7, 2026 · NOC 38425 · Supplement to a New Drug Submission (SNDS)
- TEVA-RISEDRONATEOctober 1, 2026 · NOC 38395 · Supplement to an Abbreviated New Drug Submission (SANDS)
- TEVA-DULOXETINESeptember 25, 2026 · NOC 38363 · Supplement to an Abbreviated New Drug Submission (SANDS)
- CEFAZOLIN FOR INJECTIONSeptember 25, 2026 · NOC 38364 · Supplement to a New Drug Submission (SNDS)
- TEVA-BUPROPION XLSeptember 18, 2026 · NOC 38322 · Supplement to an Abbreviated New Drug Submission (SANDS)
- TEVA-LISDEXAMFETAMINESeptember 15, 2026 · NOC 38281 · Supplement to an Abbreviated New Drug Submission (SANDS)
- TEVA-BILASTINESeptember 15, 2026 · NOC 38300 · Abbreviated New Drug Submission (ANDS)
- VINCRISTINE SULFATE INJECTIONSeptember 9, 2026 · NOC 38252 · Supplement to a New Drug Submission (SNDS)
- TEVA-SACUBITRIL / VALSARTANAugust 27, 2026 · NOC 38195 · Abbreviated New Drug Submission (ANDS)
- TEVA-VALACYCLOVIRAugust 27, 2026 · NOC 38267 · Supplement to an Abbreviated New Drug Submission (SANDS)
- TEVA-SUMATRIPTAN; TEVA-SUMATRIPTAN DFAugust 26, 2026 · NOC 38173 · Supplement to an Abbreviated New Drug Submission (SANDS)
- TEVA-FLUTICASONEAugust 18, 2026 · NOC 38129 · Supplement to an Abbreviated New Drug Submission (SANDS)
- TEVA-QUETIAPINE XRAugust 18, 2026 · NOC 38133 · Supplement to an Abbreviated New Drug Submission (SANDS)
- TEVA-FENTANYLAugust 12, 2026 · NOC 38106 · Supplement to an Abbreviated New Drug Submission (SANDS)
- TEVA-PINDOLOLAugust 7, 2026 · NOC 38079 · Supplement to a New Drug Submission (SNDS)
- TEVA-LEFLUNOMIDEJuly 31, 2026 · NOC 38028 · Supplement to an Abbreviated New Drug Submission (SANDS)
- TEVA-RASAGILINEJuly 20, 2026 · NOC 37948 · Supplement to a New Drug Submission (SNDS)
- TEVA-ROSUVASTATINJuly 13, 2026 · NOC 37903 · Supplement to an Abbreviated New Drug Submission (SANDS)
- TEVA-MYCOPHENOLATEJuly 13, 2026 · NOC 37907 · Supplement to an Abbreviated New Drug Submission (SANDS)
- TEVA-ATORVASTATINJuly 13, 2026 · NOC 37910 · Supplement to an Abbreviated New Drug Submission (SANDS)
- TEVA-DILTIAZEM CDJuly 10, 2026 · NOC 37876 · Supplement to an Abbreviated New Drug Submission (SANDS)
- TEVA-IRBESARTANJuly 10, 2026 · NOC 37885 · Supplement to an Abbreviated New Drug Submission (SANDS)
- TEVA-OMEPRAZOLEJuly 7, 2026 · NOC 37852 · Supplement to an Abbreviated New Drug Submission (SANDS)
- TEVA-TOLTERODINE LAJuly 3, 2026 · NOC 37840 · Supplement to an Abbreviated New Drug Submission (SANDS)
- TEVA-LISINOPRIL (TYPE Z)June 26, 2026 · NOC 37799 · Supplement to an Abbreviated New Drug Submission (SANDS)
- AJOVYJune 19, 2026 · NOC 37732 · Supplement to a New Drug Submission (SNDS)
- TEVA-TAMOXIFENJune 18, 2026 · NOC 37729 · Supplement to a New Drug Submission (SNDS)
- AJOVYJune 17, 2026 · NOC 37718 · Supplement to a New Drug Submission (SNDS)
- TEVA-BISOPROLOLJune 16, 2026 · NOC 37714 · Supplement to an Abbreviated New Drug Submission (SANDS)
- TEVA-MOMETASONEJune 16, 2026 · NOC 37716 · Supplement to an Abbreviated New Drug Submission (SANDS)
- TEVA-NAPROXEN; TEVA-NAPROXEN ECJune 5, 2026 · NOC 37671 · Supplement to a New Drug Submission (SNDS)
- TEVA-IMATINIBMay 29, 2026 · NOC 37653 · Supplement to an Abbreviated New Drug Submission (SANDS)
- TEVA-CLONIDINEMay 26, 2026 · NOC 37610 · Supplement to a New Drug Submission (SNDS)
- ACT CIPROFLOXACINMay 22, 2026 · NOC 37592 · Supplement to an Abbreviated New Drug Submission (SANDS)
- TEVA-LETROZOLEMay 15, 2026 · NOC 37558 · Supplement to an Abbreviated New Drug Submission (SANDS)
- TEVA-INDOMETHACINMay 13, 2026 · NOC 37531 · Supplement to a New Drug Submission (SNDS)
- TEVA-AMIODARONEMay 13, 2026 · NOC 37532 · Supplement to an Abbreviated New Drug Submission (SANDS)
- ETOPOSIDE INJECTIONMay 13, 2026 · NOC 37535 · Supplement to a New Drug Submission (SNDS)
- TEVA-ZOPICLONEMay 11, 2026 · NOC 37517 · Supplement to an Abbreviated New Drug Submission (SANDS)
- TEVA-PROGESTERONEMay 7, 2026 · NOC 37501 · Supplement to an Abbreviated New Drug Submission (SANDS)
- TEVA-PERINDOPRIL/INDAPAMIDEMay 6, 2026 · NOC 37483 · Supplement to an Abbreviated New Drug Submission (SANDS)
- TEVA-SALBUTAMOL HFAApril 30, 2026 · NOC 37442 · Supplement to a New Drug Submission (SNDS)
- EPIRUBICIN HYDROCHLORIDE INJECTIONApril 24, 2026 · NOC 37401 · Supplement to an Abbreviated New Drug Submission (SANDS)
- TEVA-PROGESTERONEApril 23, 2026 · NOC 37390 · Supplement to an Abbreviated New Drug Submission (SANDS)
- TEVA-CITALOPRAMApril 17, 2026 · NOC 37344 · Supplement to an Abbreviated New Drug Submission (SANDS)
- TEVA-MEDROXYPROGESTERONEApril 17, 2026 · NOC 37352 · Supplement to an Abbreviated New Drug Submission (SANDS)
- TEVA-APIXABANApril 14, 2026 · NOC 37321 · Supplement to an Abbreviated New Drug Submission (SANDS)
- TEVA-LORAZEPAMApril 10, 2026 · NOC 37396 · Supplement to a New Drug Submission (SNDS)
- TEVA-DILTIAZEM TApril 9, 2026 · NOC 37298 · Supplement to an Abbreviated New Drug Submission (SANDS)
- TEVA-LISDEXAMFETAMINEMarch 27, 2026 · NOC 37218 · Supplement to an Abbreviated New Drug Submission (SANDS)
- TEVA-ABACAVIR/LAMIVUDINEMarch 18, 2026 · NOC 37127 · Supplement to an Abbreviated New Drug Submission (SANDS)
- TEVA-ROSUVASTATINMarch 13, 2026 · NOC 37101 · Supplement to an Abbreviated New Drug Submission (SANDS)
- ATORVASTATINMarch 3, 2026 · NOC 37026 · Supplement to an Abbreviated New Drug Submission (SANDS)
- TEVA-DEXTROAMPHETAMINE SRFebruary 27, 2026 · NOC 37004 · Supplement to a New Drug Submission (SNDS)
- TEVA-PERINDOPRILFebruary 25, 2026 · NOC 36970 · Supplement to an Abbreviated New Drug Submission (SANDS)
- LONGAVOFebruary 25, 2026 · NOC 36982 · Supplement to a New Drug Submission (SNDS)
- TEVA-IRBESARTAN HCTZFebruary 24, 2026 · NOC 36992 · Supplement to an Abbreviated New Drug Submission (SANDS)
- TEVA-AMPHETAMINE XRFebruary 23, 2026 · NOC 36969 · Supplement to an Abbreviated New Drug Submission (SANDS)
- FLUDARABINE PHOSPHATE FOR INJECTIONFebruary 20, 2026 · NOC 36937 · Supplement to an Abbreviated New Drug Submission (SANDS)
- TEVA-ESCITALOPRAMFebruary 18, 2026 · NOC 36931 · Supplement to an Abbreviated New Drug Submission (SANDS)
- LONGAVOFebruary 10, 2026 · NOC 36874 · Supplement to a New Drug Submission (SNDS)
- TEVA-LISDEXAMFETAMINEFebruary 9, 2026 · NOC 36857 · Supplement to an Abbreviated New Drug Submission (SANDS)
- ACT METHYLPHENIDATE ERFebruary 6, 2026 · NOC 36846 · Supplement to an Abbreviated New Drug Submission (SANDS)
- VINCRISTINE SULFATE INJECTIONFebruary 6, 2026 · NOC 36861 · Supplement to a New Drug Submission (SNDS)
- AJOVYFebruary 5, 2026 · NOC 36854 · Supplement to a New Drug Submission (SNDS)
- TEVA-EMTRICITABINE/TENOFOVIRFebruary 4, 2026 · NOC 36848 · Supplement to an Abbreviated New Drug Submission (SANDS)
- TEVA-RIVAROXABANJanuary 30, 2026 · NOC 36850 · Supplement to an Abbreviated New Drug Submission (SANDS)
- TEVA-SPIRONOLACTONEJanuary 29, 2026 · NOC 36804 · Supplement to a New Drug Submission (SNDS)
- TEVA-DASATINIBJanuary 22, 2026 · NOC 36772 · Supplement to an Abbreviated New Drug Submission (SANDS)
- TEVA-GLATIRAMER ACETATEJanuary 21, 2026 · NOC 36761 · Supplement to a New Drug Submission (SNDS)
- TEVA-VORICONAZOLEJanuary 13, 2026 · NOC 36722 · Supplement to an Abbreviated New Drug Submission (SANDS)
- TEVA-CETIRIZINEJanuary 9, 2026 · NOC 36710 · Supplement to an Abbreviated New Drug Submission (SANDS)
- TEVA-GABAPENTINJanuary 2, 2026 · NOC 36670 · Supplement to an Abbreviated New Drug Submission (SANDS)
- CEFAZOLIN FOR INJECTIONDecember 29, 2025 · NOC 36641 · Supplement to a New Drug Submission (SNDS)
- TEVA-AMPHETAMINE XRDecember 24, 2025 · NOC 36631 · Supplement to an Abbreviated New Drug Submission (SANDS)
- EPIRUBICIN FOR INJECTIONDecember 23, 2025 · NOC 36627 · Supplement to an Abbreviated New Drug Submission (SANDS)
- CARBOPLATIN INJECTIONDecember 22, 2025 · NOC 36607 · Supplement to a New Drug Submission (SNDS)
- AZILECTDecember 18, 2025 · NOC 36594 · Supplement to a New Drug Submission (SNDS)
- TEVA-EVEROLIMUSDecember 17, 2025 · NOC 36569 · Supplement to an Abbreviated New Drug Submission (SANDS)
- SEASONALEDecember 17, 2025 · NOC 36589 · Supplement to a New Drug Submission (SNDS)
- TEVA-TOPIRAMATEDecember 12, 2025 · NOC 36520 · Supplement to an Abbreviated New Drug Submission (SANDS)
- TEVA-PROPOFOLDecember 12, 2025 · NOC 36524 · Supplement to an Abbreviated New Drug Submission (SANDS)
- TEVA-PIOGLITAZONEDecember 12, 2025 · NOC 36572 · Supplement to an Abbreviated New Drug Submission (SANDS)
- AVIANE 21; AVIANE 28December 11, 2025 · NOC 36517 · Supplement to an Abbreviated New Drug Submission (SANDS)
- LEUCOVORIN CALCIUM INJECTIONDecember 11, 2025 · NOC 36526 · Supplement to a New Drug Submission (SNDS)
- TEVA-ESOMEPRAZOLEDecember 3, 2025 · NOC 36472 · Supplement to an Abbreviated New Drug Submission (SANDS)
- DOXORUBICIN HYDROCHLORIDE INJECTIONNovember 21, 2025 · NOC 36414 · Supplement to an Abbreviated New Drug Submission (SANDS)
- TEVA-CLOBETASOLNovember 18, 2025 · NOC 36399 · Supplement to a New Drug Submission (SNDS)
- TEVA-PAROXETINENovember 17, 2025 · NOC 36389 · Supplement to an Abbreviated New Drug Submission (SANDS)
- TEVA-IRBESARTANNovember 16, 2025 · NOC 36392 · Supplement to an Abbreviated New Drug Submission (SANDS)
- VINBLASTINE SULPHATE INJECTIONNovember 10, 2025 · NOC 36357 · Supplement to an Abbreviated New Drug Submission (SANDS)
- ACT ESCITALOPRAM ODTOctober 29, 2025 · NOC 36282 · Supplement to an Abbreviated New Drug Submission (SANDS)
- TEVA-LISINOPRIL/HCTZ (TYPE Z)October 28, 2025 · NOC 36264 · Supplement to an Abbreviated New Drug Submission (SANDS)
- TEVA-CYPROTERONE / ETHINYL ESTRADIOLOctober 27, 2025 · NOC 36256 · Supplement to an Abbreviated New Drug Submission (SANDS)
- TEVA-LEFLUNOMIDEOctober 17, 2025 · NOC 36222 · Supplement to an Abbreviated New Drug Submission (SANDS)
- TEVA-LEVOFLOXACINOctober 16, 2025 · NOC 36178 · Supplement to an Abbreviated New Drug Submission (SANDS)
- TEVA-BUDESONIDEOctober 16, 2025 · NOC 36190 · Supplement to an Abbreviated New Drug Submission (SANDS)
- TEVA-DESVENLAFAXINEOctober 10, 2025 · NOC 36144 · Supplement to an Abbreviated New Drug Submission (SANDS)
- PORTIA 21; PORTIA 28October 7, 2025 · NOC 36119 · Supplement to an Abbreviated New Drug Submission (SANDS)
The latest 100 of 1,441.
Recalls and safety alerts that mention its products
Health Canada’s recall notices do not carry licence numbers, so these are matched by name. A notice may cover another product or only some lots: read it to see what it covers.
- Generic acetaminophen by Teva recalled because it may contain foreign materialSeptember 10, 2026 · Drugs · Contamination - Product quality · Type I
- Two lots of Teva-Pregabalin 150 mg capsules recalled due to cross-contamination with the drug sertralineAugust 15, 2026 · Drugs · Contamination · Type I
- TEVA-ECTOSONE 0.1% Cream; Affected lot may be missing lot number and expiry dateAugust 7, 2026 · Drugs · Labelling · Type II
- Teva-Indomethacin: Out of specificationFebruary 18, 2026 · Drugs · Product quality · Type II
- Seasonique, Seasonale tablets: Affected lot(s) may not contain the correct amount of tablets (missing blister card)February 13, 2026 · Drugs · Product quality · Type I
- Seasonique and Seasonale birth control pills are being recalled due to the possibility of a missing blister cardFebruary 13, 2026 · Drugs · Product quality
- Teva-Topilene Ointment 0.05%: The assay is potentially out of specification in the affected lot during its shelf life.December 18, 2025 · Drugs · Product quality · Type II
- Important Safety Information on COPAXONE (glatiramer acetate) and the Risk of Anaphylactic Reactions Which May Occur at Any Time Following Initiation of TreatmentAugust 21, 2025 · Drugs · New safety information - Product safety - Adverse reaction
- Teva-Piroxicam 10 mg capsule; Out of specification (Dissolution)June 18, 2025 · Drugs · Product quality · Type II
- Seasonique tablet; may be packaged with extra yellow tablets (ethinyl estradiol)June 6, 2025 · Drugs · Packaging · Type I
- One lot of Seasonique birth control recalled due to possible extra yellow pills (ethinyl estradiol only)June 6, 2025 · Drugs · Product quality
- Seasonale tablet: packaged with extra placebo tabletsJune 5, 2025 · Drugs · Packaging · Type I
- Two lots of Seasonale birth control recalled due to extra placebo pillsJune 4, 2025 · Drugs · Product quality
- One lot of Seasonique birth control recalled due to missing pillsMay 2, 2025 · Drugs · Product quality
- Seasonique: Affected lot may not contain the correct amount of tabletsMay 2, 2025 · Drugs · Product quality · Type I
- TEVA-Codeine Tablets: out of specification on friability test (broken tablet) during stability testing for affected lots.December 20, 2024 · Drugs · Product safety · Type II
- TEVA-Betahistine Tablets: Affected lots exceed or may exceed the interim acceptable intake limit for N-nitroso-betahistine.December 4, 2024 · Drugs · Product safety · Type I
- Recall: Teva- Bupropion 300mg - lower strength tabletAugust 9, 2024 · Drugs · Product quality · Type II
- Expanded recall: ratio-ECTOSONE (TEVA-ECTOSONE) 0.1% regular lotion and 0.05% mild lotion recalled due to an impurity that may pose health risksAugust 5, 2024 · Drugs · Product quality - Labelling · Type I
- Expanded recall: ratio-ECTOSONE (TEVA-ECTOSONE) 0.1% regular lotion and 0.05% mild lotion recalled due to an impurity that may pose health risksAugust 3, 2024 · Drugs · Product quality
- Teva-Topilene 0.05% Ointment: Out of SpecificationJune 27, 2024 · Drugs · Product quality · Type II
- TEVA-DILTIAZEM XC: Out of specificationFebruary 7, 2024 · Drugs · Health products · Type II
- Pediatrix Acetaminophen Oral Solution for children: One lot recalled due to potential risk of overdoseJanuary 17, 2024 · Drugs · Product safety
- PEDIATRIX ORAL SOLUTION 100mg: Out of specificationJanuary 15, 2024 · Drugs · Product quality · Type II
- Teva-Atenolol; Product label image incorrectNovember 21, 2022 · Drugs · Labelling · Type III
- Teva-Ectosone: product qualityMarch 2, 2022 · Drugs · Product quality · Type III
- Novo-Gesic Forte (2021-10-06)October 6, 2021 · Drugs · Product safety · Type I
- Two lots of Novo-Gesic Forte/Acetaminophen recalled due to labelling error that may lead to overdose and in the most severe cases, deathOctober 6, 2021 · Drugs
- Teva-Losartan (2021-08-26)August 26, 2021 · Drugs · Product safety · Type I
- TEVA-Losartan Product Recall (2021-05-25)May 25, 2021 · Drugs · Product safety · Type I
- Teva-Varenicline (2021-04-06)April 6, 2021 · Drugs · Product safety · Type II
- Teva-Varenicline 1mg (2021-04-06)April 6, 2021 · Drugs · Product safety · Type II
- Teva-Varenicline 0.5mg (2021-04-06)April 6, 2021 · Drugs · Product safety · Type II
- Teva-Triamterene/HCTZ (2020-07-24)July 24, 2020 · Drugs · Product safety · Type III
- Teva-Carvedilol (2020-06-05)June 5, 2020 · Drugs · Product safety · Type II
- Teva-Cotridin (2020-06-01)June 1, 2020 · Drugs · Product safety · Type III
- Teva-Ramipril (2020-01-31)January 31, 2020 · Drugs · Product safety · Type III
- Ratio-Nystatin (2019-06-27)June 27, 2019 · Drugs · Product safety · Type III
- TEVA-LOSARTAN/HCTZ (2019-03-06)March 6, 2019 · Drugs · Product safety · Type I
- Ratio-Nystatin (2019-02-28)February 28, 2019 · Drugs · Product safety · Type III
- Teva-Levocarbidopa (2018-01-17)January 17, 2018 · Drugs · Product safety · Type III
- NOVASEN 325mg ENTERIC COATED TABLETS (DELAYED RELEASE) (2017-11-27)December 7, 2017 · Drugs · Product safety · Type III
- Novamoxin (2017-11-07)November 16, 2017 · Drugs · Product safety · Type III
- Teva-Valsartan (2017-05-11)June 22, 2017 · Drugs · Product safety · Type III
- Teva-Lorazepam 0.5 mg (2017-02-09)February 23, 2017 · Drugs · Product safety · Type III
- Teva-Lorazepam 1 mg (2017-02-09)February 22, 2017 · Drugs · Product safety · Type III
- Novamoxin (2016-08-18)September 20, 2016 · Drugs · Product safety · Type III
- Teva-Tolterodine (2016-08-04)August 11, 2016 · Drugs · Product safety · Type II
- Teva-Ranitidine (2016-06-09)June 17, 2016 · Drugs · Product safety · Type II
- Methoxacet - C1/8 (2016-01-22)February 2, 2016 · Drugs · Product safety · Type III
- Teva-Fluvastatin (2015-10-16)October 26, 2015 · Drugs · Product safety · Type II
- Teva-Travoprost Z Ophthalmic Solution (2015-08-28)September 2, 2015 · Drugs · Product safety · Type III
- ratio-Atorvastatin recall (2014-07-08)July 17, 2014 · Drugs · Product safety · Type II
- IMURAN (azathioprine) or PURINETHOL (mercaptopurine) - Association with a Type of Blood Cancer - Hepatosplenic T-Cell Lymphoma - For the PublicMarch 26, 2014 · Drugs · Product safety
- IMURAN (azathioprine) or PURINETHOL (mercaptopurine) - Association with a Type of Blood Cancer - Hepatosplenic T-Cell Lymphoma - For Health ProfessionalsMarch 26, 2014 · Drugs · Product safety
- Teva-Galantamine ER (2013-12-12)January 3, 2014 · Drugs · Product safety · Type II
- Ratio-MetforminJuly 17, 2013 · Drugs · Product safety · Type II
- Teva-Ramipril (2.5 mg and 5 mg)April 23, 2013 · Drugs · Product safety · Type II
- SeasonaleApril 2, 2013 · Drugs · Product safety · Type III
- Novo-GesicApril 2, 2013 · Drugs · Product safety · Type II
- Teva-MirtazapineApril 30, 2012 · Drugs · Type II
- One Lot of Zaditen Tablets (for Asthma) Recalled Due to Potential Health RisksDecember 4, 2009 · Drugs · Labelling
- Authorized Sleep-Aid Medications in CanadaOctober 7, 2009 · Drugs
- Important Safety Information on ratio-Metformin 500mg lot 638812 - For Health ProfessionalsJuly 25, 2008 · Drugs
- Ratio-Morphine Tablets Recalled in Canada due to Risk of Accidental Overdose - For Health ProfessionalsJuly 14, 2008 · Drugs
- Archived – Ratio-Morphine Tablets Recalled in Canada due to Risk of Accidental OverdoseJuly 9, 2008 · Drugs · Dosage - Labelling